Infographics

1. Top 5 improvements Needed In Today’s EDC Software Systems 2/16/2021

   In Q3, 2020, ISR asked 130 respondents responsible for outsourcing EDC how they would improve todays EDC software systems. More user-friendly/intuitive interface topped the list, capturing 32% of respondent’s votes. Followed by Better system integration (26%), Increase speed (of build, setup, testing, functions) (19%), Design flexibility/customizable (17%), and More/better data capabilities (12%) rounding out the top five.

2. How To Improve eCOA/ePRO Software Systems 1/15/2021

   In Q3, 2020, ISR asked 118 respondents involved in clinical trials what eCOA/ePRO software systems needed to improve upon. Improve integration (with EDC, other systems & devices) topped the list, capturing 28% of respondent’s votes. Followed by More user-friendly (22%) and System design (flexibility, robustness, etc.) (16%) rounding out the top three.

3. Technology In Clinical Trials: Differences By Company Size 1/12/2021

   When looking at industrywide trends, it’s helpful to remember that large sponsors have more resources to help them pursue new technology initiatives. With that in mind, we took a look at where large vs. nonlarge sponsors differ in terms of openness to emerging trends in clinical development. The largest differences are highlighted both in the tables below and their associated graphs.

4. Why Phase II/III Service Providers Lose Bids 11/13/2020

   In Q2, 2020, ISR asked 146 respondents involved in outsourcing Phase II/III services what is the main reason a CRO may lose bids for Phase II/III work. High cost topped the list, capturing 37% of respondents’ votes. Followed by Lack of therapeutic experience (19%) and Lack of understanding of the trial outcomes (12%).

5. Patient Recruitment Challenges In Rare Disease Studies 10/15/2020

   In Q2, 2020, ISR asked 125 respondents involved in patient recruitment and retention activities for rare disease studies about challenges they face while recruiting patients. The data below show the most challenging issue reported by respondents in finding patients for their recent rare disease studies was Multiple sites with access to only a few patients (42%). Followed by Multiple entities pursuing same small pool of patients (19%) and Rigid inclusion/exclusion criteria leading to high screenout rate (15%).

6. Central IRB Outsourcing Practices By Company Size 8/17/2020

   In Q3, 2019, ISR asked outsourcers of Central IRB services about how uniform the use of Central IRBs is within their organization. In terms of company size, respondents from small companies report that their company uses the same Central IRB on All or most of the studies at a higher rate than those from large companies (45% vs 38%). Mid-size companies were similar to large companies, with 37% of respondents reporting their company used the same Central IRB for all studies.

7. Most Important Selection Criteria For Central IRB Services 7/15/2020

   In Q3, 2019, ISR asked 111 respondents responsible for the selection of Central IRB services about the most important attributes when choosing a Central IRB. Not surprisingly, communication and timeliness are highly valued. Clearly communicates expectations for submissions, Defines time-frames for review and reporting, Is fully AAHRPP accredited, Provides excellent customer service, and Offers fast turnaround time are the most important attributes with more than half of respondents considering them moderately or very important when selecting a Central IRB. 

8. 3 Year Rolling Average – Phase I Service Provider Customer Loyalty 5/12/2020

   In Q4, 2019, ISR asked sponsors who outsource phase I trials to better understand customer loyalty. CRO loyalty is computed as an index that consists of likelihood to recommend, likelihood to use again, and overall satisfaction. The data below show companies with twenty or more user ratings over the past 3 years and an industry average derived from all CROs included in the research.

9. Most Important Capabilities For Pharmacovigilance Services 4/16/2020

   In Q4, 2019, ISR asked outsourcers of drug safety / pharmacovigilance services about the most important capabilities when choosing a pharmacovigilance provider. Regulatory compliance tops the list as the most important capability for service provider selection. Half of respondents picked it among their top five capabilities and 15% of respondents selected it as the most important capability. 

10. Preferred Provider Use Among Bioanalytical Lab Outsourcers 3/13/2020

    In Q3, 2019, ISR asked outsourcers of bioanalytical lab services about their organization’s use of preferred providers. The data show use of preferred providers is common practice when outsourcing bioanalytical lab work, 88% currently use a preferred lab for preclinical services and 90% currently use a preferred lab for clinical services. On average, respondents indicate that their company currently has 2.3 preferred labs for preclinical services and 2.6 preferred labs for clinical lab work. For more information, follow the link to the Bioanalytical Labs Market Dynamics and Service Provider Performance report preview.